Loading
M108 is an experimental monoclonal antibody from FutureGen Biopharmaceutical (Beijing) in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.
M108 is a monoclonal antibody developed by FutureGen Biopharmaceutical (Beijing). Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). ClinicalTrials.gov describes the intervention as: M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06177041 (M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma), in gastric & gastro-oesophageal junction cancer. The largest, NCT06177041, plans to enrol 486 participants with primary completion expected 2027-01-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Monoclonal antibody directed at Claudin 18.2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to Claudin 18.2.
1.M108 binds Claudin 18.2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"M108" OR ABSTRACT:"M108" OR TITLE:"M108 monoclonal antibody" OR ABSTRACT:"M108 monoclonal antibody") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about M108, not a curated reading list.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.